XII International Symposium on Blood Substitute
It is a very exciting and critical time for Hemoglobin-based Oxygen Carriers (HBOC) research in light of recent findings, such as those published in JAMA (Natanson et al., 2008, 299, 2304-12), Proc. Natl. Acad. Sci USA (Reynolds et al., 2007, 104, 17058-62; Bennett-Guerrero et al., 2007, 104, 17063-68), and Transfusion (Estep et al. 2008, 48, 776-82), and the outcome of the workshop organized in Bethesda by the FDA on April 29-30 (http://www.fda.gov/cber/blood/hboc042908.htm).
The Symposium in Parma will be a great occasion i) to evaluate pathophysiology conditions that may take advantage of the availability of HBOC; ii) to understand oxygen and nitric oxide homeostasis in the absence and presence of HBOC; iii) to assess the relevance of clinical trials and whether the present FDA regulation assured the development of safe and effective HBOC, and iv) to highlight novel approaches for the development of HBOCs.
It is also a very sad time as Dr. Bob Winslow passed away on February 2, 2009. He was a pioneer in the investigation of hemoglobin and hemoglobin-based oxygen carriers. Friends and colleagues will remember him in a special session.
Goto the website